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Scope: In vitro and in vivo studies suggest that dietary anthocyanins modulate cardiovas-
cular disease risk; however, given anthocyanins extensive metabolism, it is likely that their
degradation products and conjugated metabolites are responsible for this reported bioactivity.
Methods and results: Human vascular endothelial cells were stimulated with either oxidized
LDL (oxLDL) or cluster of differentiation 40 ligand (CD40L) and cotreated with cyanidin-3-
glucoside and 11 of its recently identified metabolites, at 0.1, 1, and 10 M concentrations.
Protein and gene expression of IL-6 and VCAM-1 was quantified by ELISA and RT-qPCR. In
oxLDL-stimulated cells the parent anthocyanin had no effect on IL-6 production, whereas nu-
merous anthocyanin metabolites significantly reduced IL-6 protein levels; phase II conjugates
of protocatechuic acid produced the greatest effects (>75% reduction, p  0.05). In CD40L-
stimulated cells the anthocyanin and its phase II metabolites reduced IL-6 protein production,
where protocatechuic acid-4-sulfate induced the greatest reduction (>96% reduction, p 0.03).
Similarly, the anthocyanin and itsmetabolites reducedVCAM-1 protein production, with ferulic
acid producing the greatest effect (>65% reduction, p  0.04).
Conclusion: These novel data provide evidence to suggest that anthocyanin metabolites are
bioactive at physiologically relevant concentrations and have the potential to modulate cardio-
vascular disease progression by altering the expression of inflammatory mediators.
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1 Introduction
Habitual intake of anthocyanins has been associatedwith a re-
duced incidence of cardiovascular disease (CVD) [1]. Studies
exploring the mechanism of action behind this activity have
primarily focused on vascular reactivity, such as endothelial-
dependent nitric oxide mediated vasodilation and blood pres-
Correspondence: Colin D. Kay
E-mail: colin.kay@uea.ac.uk
Abbreviations: CD40, cluster of differentiation 40; CD40L, CD40
ligand; CVD, cardiovascular disease; C3G, cyanidin-3-glucoside;
HUVEC, human umbilical vein endothelial cells; IVA, isovanil-
lic acid; oxLDL, oxidized LDL; PCA, protocatechuic acid; PGA,
phloroglucinaldehyde; TNF-, tumor necrosis factor-alpha; TRAF,
TNF receptor-associated factor; VA, vanillic acid; VCAM-1, vascu-
lar cell adhesion molecule-1
sure regulation [2–4]. Recently researchers have begun to ex-
plore anti-inflammatory activities of anthocyanins as a poten-
tial cardioprotective mechanism of action and there is now
evidence to suggest that anthocyanins may modulate the pro-
duction of key inflammatory mediators, including IL-6 and
vascular cell adhesion molecule-1 (VCAM-1) [5–7].
Cell adhesion molecules such as VCAM-1 play a key role
in the progression of atherosclerosis as they are involved in
the adhesion of leukocytes to the endothelium during the
early stages of atherosclerosis [8, 9]. Following leukocyte ad-
hesion, IL-6 is secreted, which further perpetuates inflam-
mation, with eventual progression to atherosclerosis [10–12].
Anthocyanins, in vivo and in vitro, have been demonstrated
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Figure 1. Recently identified metabolites of C3G1 screened for their activity against IL-6 and VCAM-1 expression in oxLDL- and CD40L-
stimulated HUVECs. C3G, cyanidin-3-glucoside; PCA, protocatechuic acid, PGA, phloroglucinaldehyde; VA, vanillic acid; IVA, isovanillic
acid; PCA-4-Gluc, PCA-4-glucuronide; PCA-3-Gluc, PCA-3-glucuronide; PCA-4-Sulf, PCA-4-sulfate; PCA-3-Sulf, PCA-3-sulfate; VA-4-Sulf,
VA-4-sulfate; IVA-3-Sulf, IVA-3-sulfate; FA, ferulic acid. 1Metabolites recently identified and reported by de Ferrars [25].
to modulate the expression of both IL-6 and VCAM-1 [13–15].
Studies feeding anthocyanin-rich bilberry and strawberry bev-
erages to human participants with elevated risk of CVD re-
ported reduced plasma concentrations of IL-6 and C-reactive
protein [7,13,16]. This is also supported by animal and in vitro
studies that demonstrated that IL-6 production can be atten-
uated by anthocyanins [14, 17]. In addition, black soybean
anthocyanins have been observed to reduce VCAM-1 produc-
tion in tumor necrosis factor- (TNF-)-challenged human
endothelial cells and protect against ischemia-induced my-
ocardial injury inmice [5,15]. In previous studies the assump-
tion is, parent anthocyanins are responsible for the observed
biological activity. However, due to the biological instability
and extensive metabolism of anthocyanins [18], we propose
that the anti-inflammatory bioactivity results from the activity
of anthocyanin degradation products andmetabolites and not
the parent anthocyanins directly.
Evidence suggests that after consumption, cyanidin-3-
glucoside (C3G) degrades to form protocatechuic acid (PCA)
and phloroglucinaldehyde (PGA) [18]. Previous in vitro stud-
ies have shown that phenolic acids, including PCA and
the methylated derivative of PCA, vanillic acid (VA), reduce
VCAM-1 production in endothelial cells and IL-6 produc-
tion in mouse peritoneal macrophages, respectively [19, 20].
Therefore it is likely that these and other metabolites of simi-
lar structure contribute towards the anti-inflammatory prop-
erties of anthocyanins. However, presently we have no un-
derstanding of the anti-inflammatory activity of the majority
of anthocyanin metabolites, as we have only recently estab-
lished the identity of the phenolic structures in humans [18].
Here we examine the effects of C3G, its degradation products
(PCA and PGA) and novel phase II conjugates (methyl, sul-
fate, glucuronide; Fig. 1) at concentrations observed in vivo
(0.1–10 M) [18], on IL-6 and VCAM-1 protein production in
humanumbilical vein endothelial cells (HUVECs) stimulated
with either oxidized LDL (oxLDL) or a cluster of differentia-
tion 40 ligand (CD40L).
2 Materials and methods
2.1 Materials
HUVEC, large vessel endothelial cell growthmedium, growth
factors and antibiotic (Amphotericin B/Gentamycin 1000 ×
concentrated) supplements were obtained from TCS cell
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works (Buckingham, UK) while RPMI 1640 media, FBS, glu-
tamine and penicillin/streptomycin were from PAA (Kent,
UK). D1.1 cells were generously provided by Dr. Maria
O’Connell, Department of Pharmacy, University of East An-
glia (Norwich, UK). Monoclonal Antibody against cluster
of differentiation 40 (CD40) was purchased from Enzo bio-
science (Cambridge, UK). LDLwas purchased fromMillipore
(UK). Cyanidin-3-glucoside was purchased from Extrasyn-
these (Genay Cedex, France). Phase II conjugates of pheno-
lic acids (PCA-3-glucuronide, PCA-4-glucuronide, isovanil-
lic acid-3-sulfate, PCA-4-sulfate, VA-4-sulfate, PCA-3-sulfate)
were synthesized by St. Andrews University as described pre-
viously [21]. DuoSet ELISA kits [IL-6 (DY206) and VCAM-1
(DY809)], flat bottom clear polystyrene 96 wells ELISA plates
(DY990) and reagent diluent (DY995) were purchased from
R&D systems Europe, UK. ELISA protein quantification
was established using an Omega BMG plate reader (BMG
Labtech, Aylesbury, UK). TRIzol
R©
reagent was purchased
from Life Technologies (Paisley, UK). RiboLock RNase in-
hibitor, DNase reaction buffer (with MgCl2), DNase I (RNase
free), EDTA (50 mM) were purchased from Fisher Scientific
(Loughborough, UK). Chloroform (molecular biology grade),
isopropanol/propan-2-ol and dNTP PCR mix (ready mixed
10 mM) were obtained from Fisher Scientific (Loughbor-
ough,UK). PCRPrimers andReal TimePCRmastermixwith
SYBR green were supplied by Primer Design (Southhamp-
ton, UK), Oligo (dT) primers were purchased from Ambion,
Life Technologies (Paisley,UK) and SuperScript
R©
II Reverse
Transcriptase, first strand buffer and DTT (100 mM) were
from Invitrogen (Paisley, UK). The RT-qPCR was performed
using ABIS7500 system, Life Technologies (Paisley, UK). All
other chemicals were from Sigma-Aldrich (Dorset, UK).
2.2 Preparation of cell treatments
C3G, PCA, PGA, VA, isovanillic acid (IVA), PCA-
4-glucuronide, PCA-3-glucuronide, PCA-4-sulfate, PCA-3-
sulfate, vanillic acid-4-sulfate, IVA-3-sulfate and ferulic acid
were assessed at concentrations of 0.1, 1 and 10M in cell
culture media. Standard solutions were initially prepared in
100%DMSO at concentrations of 40mM for C3G and 25mM
for all other metabolites followed by dilution to final concen-
trations (0.1, 1 and 10 M) using cell media, immediately
prior to application to cells. Final treatment concentration of
DMSO was 0.05%.
2.3 Cell culture and assays
Early passage, pooled donor HUVECs were used between
passages 2–4 and cultured in large vessel endothelial cell
growth medium at 37C and 5% CO2. HUVECs were sub-
cultured at90% confluence by trypsinisation and seeded at
60 000 cells/well in 24-well plates on fibronectin coated sur-
face (0.25 g/cm2) for cell assays. D1.1 cells were maintained
in suspension between 6× 105 cells/mL and 1× 106 cells/mL
in RPMI media at 37C and 5% CO2. For oxLDL-stimulated
experiments, oxLDLwas prepared as previously described [22]
and 90%confluentHUVECswere co-incubatedwith 5g/mL
oxLDLwith orwithout treatment compounds for 24 h. The ox-
idation of LDL was confirmed by agarose gel electrophoresis
[23]. For CD40L-stimulated assays, 90% confluent HUVECs
were co-incubatedwithD1.1 cells at 1× 106 cells/well, with or
without treatments for 24 h. The specificity of CD40L stimula-
tion was confirmed by pre-incubation of D1.1 cells at 1 × 106
cells/well with anti-CD40L (5g/mL) for 1 h followed by their
incubation with HUVECs for 24 h. Post 24 h co-incubation,
supernatants and culture plates were stored immediately at
–80C until required for protein and mRNA quantification,
except 24-well plates for the CD40L-stimulated assay, where
the HUVECs were washed three times with 1% warm PBS to
remove D1.1 cells before plates were stored at –80C.
2.4 IL-6 and VCAM-1 protein quantification by ELISA
Cell supernatants (100 L) were used to quantify IL-6 and
VCAM-1 using commercially available DuoSet ELISA kits
(according to manufacturer’s instructions). Briefly, 96-well
plates were coated with mouse anti-human IL-6 and VCAM-1
primary antibodies followed by incubation for 2 h at room
temperature with cell supernatants. Subsequently, plates
were incubated with goat anti-human IL-6 and VCAM-1
secondary antibodies for 2 h, followed by the addition of
horseradish-peroxidase conjugated streptavidin HRP, sub-
strate reagents, stabilized H2O2 and tetramethylbenzidine.
The color was developed using 2N H2SO4 stop solution
(50 L/well) that was measured at 450 nm using a BMG
plate reader. The IL-6 ELISA intra- and inter-assay CV was
4.3 ± 1.3% and 1.49%, respectively (mean ± SD, n = 4). The
VCAM-1 intra- and inter-assay CVwas 7.6± 2.2% and 0.69%,
respectively (mean ± SD, n = 4).
2.5 Quantitative real-time PCR
RNA extraction fromHUVECs was performed using phenol-
chloroform extraction (TRIzol
R©
, 500 L/well). RNA was
quantified using a NanoDrop
R©
2000 (purity ratio A260/280).
One micro-gram of RNA was prepared for reverse transcrip-
tion by incubations with RiboLock (0.25 L/reaction), DNase
buffer (1 L/reaction) and DNase (1 L/reaction) at 37C for
30 min, followed by incubation with EDTA (50 mM, 1 L/
reaction), oligo (dT) primers (1 L/reaction) and dNTP PCR
mix (1L/reaction) at 65C for 10min followed by first strand
buffer (4 L/reaction), RiboLock (1 L/reaction) and DTT
(100mM, 1L/reaction) for 2min at 42C. Reverse transcrip-
tion was carried out using SuperScript
R©
II (1 L/reaction)
at 42C for 50 min followed by inactivation for 15 min at
70C. Five micro-liters of 1:10 diluted cDNA solutions (25 ng)
was added to plates containing IL-6 and VCAM-1 primers
(1L/reaction), real-time PCRmastermix with SYBR
R©
green
(8.33L/reaction) andnuclease-freewater (5.67L/reaction).
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The RT-qPCR was performed using an ABIS7500 where the
enzymes were activated at 95C for 10 min followed by 50
cycles of denaturation (15 s/cycle at 95C) and data collection
(1 min/cycle at 60C). Target genes, were normalized against
two geNorm housekeeping reference genes, UBE2D2 and
PRDM4 as established using qbasePLUS2 [Biogazelle (Zwin-
jaarde, Belgium)]. The fold expression of the target geneswere
quantified by 2Ct determination, where Ct = Ct target gene/Ct
mean Ct of references gene. Forward and reverse primer sequence for
IL-6 was GCA GAA AAC AAC CTG AAC CTT and ACC TCA
AAC TCC AAA AGA CCA and CAG GCT AAG TTA CAT
ATT GAT GAC AT and GAG GAA GGG CTG ACC AAG AC
for VCAM-1.
2.6 Statistical analysis
Analysis of variance with Tukey post-hoc tests were per-
formed using SPSS software (IBM, New York, USA) ver-
sion 18 for Windows. Significance was determined at the
level of 5%. Three biological replicates for each of the con-
trols and treatments (plated in technical duplicates) were used
for analysis unless otherwise stated, and means of biological
replicates were represented graphically. Error bars in figures
represent SD.
3 Results
3.1 OxLDL-stimulated IL-6 and VCAM-1 production
OxLDL-stimulation resulted in a 6.9 ± 0.4-fold increase in
IL-6 protein relative to the un-stimulated control (p  0.001,
Fig. 2A); whereas there was no effect of oxLDL on VCAM-
1 protein production (data not shown). There was no effect
of the parent anthocyanin under oxLDL stimulated condi-
tions, while nine metabolites reduced oxLDL-induced IL-6
production by >32% (p  0.05, Fig. 2) relative to the cells
treated with oxLDL alone (oxLDL control), at one or more of
the tested treatment concentrations (0.1, 1, 10 M). PCA, re-
duced IL-6 production by 53.6 ± 7.6% (p  0.001, Fig. 2B)
while PGAhad no effect. Among themethyl, glucuronide and
sulfate conjugated metabolites of PCA, PCA glucuronides
and PCA sulfates elicited the greatest reductions in IL-6 pro-
duction (across all concentrations tested), with maximum
reductions (99.1 ± 0.1%, p  0.001) observed for the sul-
fate conjugates (Fig. 2C–E). In addition, VA-4-sulfate, IVA-
3-sulfate and ferulic acid also displayed bioactivity against
oxLDL-induced IL-6 production (between 54.1 ± 4.4 and 98.2
± 0.2% reduction, p  0.05; Fig. 2F and G).
3.2 OxLDL-stimulated IL-6 mRNA levels
The compounds that elicited reductions in IL-6 protein (re-
ported above) were further investigated for their effects on
IL-6 mRNA levels using RT-qPCR following incubation with
treatment compounds at their highest tested concentration
(10 M), for 24 h. IL-6 mRNA expression was increased by
3.5 ± 0.9-fold (p < 0.05, Fig. 3) in cells treated with oxLDL
alone (oxLDL control) compared to un-stimulated cells. All
compounds except ferulic acid reduced oxLDL-induced IL-6
mRNA expression by  55.2 ± 7.3% of the oxLDL control
(p 0.006, Fig. 3). VA exhibited the greatest reduction in IL-6
mRNA levels, displaying an 82.9 ± 10.4% reduction relative
to the control (p  0.001).
3.3 CD40L-stimulated IL-6 and VCAM-1 production
IL-6 protein expression was significantly increased (3.2± 1.5-
fold) in CD40L-treated HUVECs but reduced (44.4 ± 1.7%)
when D1.1 cells were pre-incubated with anti-CD40L anti-
body, suggesting a direct role of CD40L in the production
of IL-6 in the present model (Fig. 4A). The parent antho-
cyanin and seven metabolites reduced CD40L-induced IL-6
protein production by 41.7 ± 3.5%, relative to cells treated
with CD40L alone (CD40L control) (p  0.03, Fig. 4). C3G
and PCA both reduced IL-6 protein production by 44.6 ±
23.0% of the control (p < 0.05, Fig. 4B), while there was
no effect of PGA. The conjugated metabolites of PCA, VA,
IVA, PCA-3-glucuronide, PCA-3-sulfate, PCA-4-sulfate, and
IVA-3-sulfate, reduced CD40L induced IL-6 production by
41.7 ± 3.5% (p0.03) for at least one of the concentrations
tested (Fig. 4C–F), with amaximum reduction of 95.8± 1.3%
(p  0.001) observed for the sulfate conjugate of PCA, PCA-
4-sulfate (Fig. 4E).
Co-incubation of CD40L expressing D1.1 cells with HU-
VECs resulted in a 13.5 ± 1.3-fold increase in VCAM-1 pro-
tein production compared to un-stimulated HUVECs (p 
0.001, Fig. 5A). This effect was significantly reduced by
11.8 ± 0.4-fold when D1.1 cells were pre-incubated with anti-
CD40L antibody. The parent anthocyanin and six metabolites
reduced CD40L-induced VCAM-1 protein production by 
26.1± 8.8% (p 0.05) relative to the cells treated with CD40L
alone (CD40L control). C3G, PCA and PGA reduced CD40L-
induced VCAM-1 by 26.1 ± 8.8% (p  0.05; Fig. 5B), while
the conjugated metabolites of PCA, VA, IVA, PCA-4-sulfate
and ferulic acid, were more active, reducing VCAM-1 pro-
duction by 30.3 ± 4.5% (p  0.04), at one or more of the
concentrations tested (Fig. 5C, E and G). The maximum re-
duction was observed for ferulic acid (65.9± 8.1%; p 0.001,
Fig. 5G). An increase in VCAM-1 protein production was
observed when CD40L-induced HUVECs were co-incubated
with PCA-4-sulfate (203.5 ± 4.5% at 1 M, p  0.001), PCA-
3-sulfate (126.5 ± 10.6% at 1 M, p  0.04) and VA-4-sulfate
(140.1 ± 10.8% at 0.1 M and 180.3 ± 2.2% at 10 M, p 
0.001) relative to CD40L-induced control (Fig. 5E and F).
3.4 CD40L-stimulated IL-6 and VCAM-1 mRNA levels
The parent anthocyanin and seven metabolites that reduced
CD40L-induced IL-6 production as reported above, were
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 2. OxLDL-stimulated IL-6 production in HUVECs co-incubated with C3G, phenolic metabolites or LDL controls for 24 h. (A) cells
incubated with or without LDL (5 g/mL); (B–G) cells incubated with C3G or phenolic metabolites at 0.1, 1 and 10 M and oxLDL. All data
expressed as mean percentage (± SD, n = 3) of oxLDL-induced controls (expressed as 100%). ***p  0.001, **p  0.01, *p  0.05 (analysis
of variance (ANOVA) with Tukey post-hoc) relative to oxLDL-stimulated control cells. C3G, cyanidin-3-glucoside; PCA, protocatechuic
acid; PGA, phloroglucinaldehyde; VA, vanillic acid; IVA, isovanillic acid; PCA-4-Gluc, PCA-4-glucuronide; PCA-3-Gluc, PCA-3-glucuronide;
PCA-3-Sulf, PCA-3-sulfate; PCA-4-Sulf, PCA-4-sulfate; VA-4-Sulf, VA-4-sulfate; IVA-3-Sulf, IVA-3-sulfate; FA, ferulic acid.
further investigated for their effects on IL-6 mRNA levels
using RT-qPCR following incubations with the treatment
compounds at 10 M for 24 h. CD40L stimulation increased
IL-6 mRNA expression in HUVECs by 2.3 ± 0.3-fold (p 
0.05, Fig. 6A), while anti-CD40L reduced this below the levels
observed in untreated HUVECs (0.2 ± 0.1-fold, p  0.05).
With the exception of IVA, all compounds reduced the levels
of CD40L-induced IL-6 mRNA by 85.3 ± 2.5% (p  0.01,
Fig. 6A) relative to the CD40L-treated control. PCA caused the
greatest reduction in CD40L-induced IL-6 mRNA expression,
where IL-6 mRNA levels were reduced by 94.9 ± 8.3% of the
CD40L-induced control (p  0.001).
The compounds which decreased CD40L-induced VCAM-
1 protein concentrations (reported above) were investigated
for their effects on CD40L-induced VCAM-1 mRNA levels,
where VCAM-1 mRNA was increased by 130.2 ± 46.1-fold
relative to untreated cells (p < 0.05, n = 3, Fig. 6B) and
reduced by 96.4± 1.2-foldwhenD1.1 cells pre-incubatedwith
anti-CD40L antibody (p  0.05). The parent anthocyanin did
not significantly reduce VCAM-1 mRNA levels while four of
the six metabolites tested reduced VCAM-1 mRNA by 81.4
± 7.2 (p 0.05, Fig. 6B). The greatest reduction in VCAM-1
mRNA levels was observed for VA, which reduced CD40L-
induced VCAM-1 by99.9 ± 0.01% of the control (p 0.04).
4 Discussion
Epidemiological studies suggest greater levels of anthocyanin
consumption are associated with a reduction in CVD risk [1],
however, themechanismsbehind this association remain elu-
sive. Most previous animal and in vitro studies have focused
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 3. Change in OxLDL-stimulated IL-
6 mRNA in HUVECs co-incubated with
C3G and phenolic metabolites at 10 M or
oxLDL controls for 24 h. All graphical data
expressed as mean fold change (± SD,
n = 3) of un-stimulated (basal) IL-6 mRNA
levels. *p  0.05 (ANOVA with Tukey
post-hoc) relative to oxLDL-stimulated
control. PCA, protocatechuic acid; VA,
vanillic acid; PCA-3-Sulf, PCA-3-sulfate;
PCA-4-Sulf, PCA-4-sulfate; VA-4-Sulf, VA-
4-sulfate; IVA-3-Sulf, IVA-3-sulfate; FA,
ferulic acid.
on the activity of the parent (un-metabolized) anthocyanins
in models of vascular function [5–7]. The present study ex-
plored the activity of metabolites of anthocyanins which we
recently identified in a stable isotope-labelled anthocyanin
intervention in humans [18]. To the best of our knowledge
this is the first in vitro study to examine the relative bioac-
tivity of recently identified metabolites relative to their par-
ent anthocyanin, using pure synthetic phase II conjugates at
physiologically relevant concentrations. In the present study,
we screened anthocyanin metabolites across a dose range of
0.1–10 M, as it represents the relative concentration range
observed following the consumption of anthocyanins in two
recent studies in our lab [24, 25]. Here, phenolic metabolites
were reported ranging from 0.1–2 M, with cumulative con-
centrations ofmetabolites reaching 10M. It should be noted
that there was considerable variation in metabolite concen-
trations between individuals.
As anthocyanins have been shown to reduce oxLDL-
induced apoptosis [26] and dampen the effect of CD40-
CD40L interaction in endothelial cells [14], the activity of
anthocyanin metabolites was explored using oxLDL- and
CD40L-stimulated endothelial cells. Here, we found that
metabolites of C3G induced greater reductions in IL-6 and
VCAM-1 protein compared to their parent structure, under
both oxLDL and CD40L stimulation. This finding suggests
that the degradation and subsequent metabolism of antho-
cyanins does not reduce their bioactivity and may in fact
increase it.
Oxidized LDL is a potent chronic inflammatory activa-
tor and an established risk factor for CVD [27]. OxLDL
has also been shown to increase the levels of IL-6 in vas-
cular endothelial cells [28], however, very little is currently
known of the effects of physiologically relevant anthocyanin
metabolites on oxLDL-mediated inflammation. As oxLDL is
known to be proapoptotic at high concentrations (such as
100 g/mL) [29], the present study utilized considerably
lower concentrations (5 g/mL) than many previous inves-
tigations [28] in an attempt to create a more physiologi-
cally relevant model of vascular dysfunction. The levels uti-
lized in the present investigation are comparable to levels
identified in the blood of patients with coronary artery dis-
ease [27]. The present study is the first to investigate the ef-
fects of C3G metabolites on oxLDL-induced IL-6 production
in vitro, and our findings suggest that the anti-inflammatory
effect of anthocyanins are not limited to the parent struc-
tures themselves, as their lower molecular weight phenolic
metabolites displayed even greater bioactivity, as observed by
reductions in oxLDL-induced IL-6 production by as much as
99% of control cells (Fig. 2E). This suggests that degrada-
tion and subsequent metabolic conjugation does not reduce
the biological activity of anthocyanins but in some instances
enhances it.
The activation of CD40 via its ligand, CD40L, is also as-
sociated with promoting chronic inflammation and the ex-
pression of pro-inflammatory mediators, including IL-6 [14]
and VCAM-1 [30] and therefore plays a pivotal role in the
development of CVD. Very little is currently known of the ef-
fect of C3G metabolites on CD40L-mediated inflammation.
We observed extensive bioactivity of the phenolic metabolites
relative to the parent anthocyanin, as observed by a reduc-
tion in CD40L-induced IL-6 and VCAM-1 by as much as 95
and 65%, respectively (Figs 4E and 5G). The effects of C3G
on CD40L-induced IL-6 and VCAM-1 have previously been
reported, where Xia et al. [14, 31] observed a significant re-
duction in CD40L-induced IL-6 and VCAM-1 following incu-
bation with C3G. Our findings are in accordance with this
previous work and provide additional evidence for the activity
of C3G metabolites.
In oxLDL-stimulated HUVECs, the parent C3G had no ef-
fect on IL-6 production, while many of the metabolites tested
significantly decreased IL-6 (Fig. 2). Amongst these, one
of the degradation products, PCA, reduced oxLDL-induced
IL-6 significantly, whereas PGA had no effect (Fig. 2B);
suggesting the degradation of C3G to PCA may increase
the bioactivity of the parent anthocyanin. All PCA conju-
gates tested, except IVA, reduced oxLDL-induced IL-6 sig-
nificantly (32–99% reduction, Fig. 2C–G), suggesting further
metabolism through methylation, glucuronidation or sulfa-
tion does not result in decreased bioactivity. Sulfate conjuga-
tion reduced oxLDL-induced IL-6 production to the greatest
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 4. CD40L-stimulated IL-6 protein production in HUVECs co-incubated with C3G, phenolic metabolites or CD40L controls for 24 h.
(A) Cells incubated with or without D1.1 cells (1 × 106 cells/well); (B–G) cells incubated with C3G or phenolic metabolites at 0.1, 1, 10 M
and D1.1 cells (1 × 106 cells/well). All data expressed as mean percentage (± SD, n = 3) of CD40L-induced controls. ***p  0.001, **p  0.01,
*p  0.05 (ANOVA with Tukey post-hoc) relative to CD40L-stimulated control. C3G, cyanidin-3-glucoside; PCA, protocatechuic acid; PGA,
phloroglucinaldehyde; VA, vanillic acid; IVA, isovanillic acid; PCA-4-Gluc, PCA-4-glucuronide; PCA-3-Gluc, PCA-3-glucuronide; PCA-3-Sulf,
PCA-3-sulfate; PCA-4-Sulf, PCA-4-sulfate; VA-4-Sulf, VA-4-sulfate; IVA-3-Sulf, IVA-3-sulfate; FA, ferulic acid.
extent, compared to other conjugation reactions (methylation
or glucuronidation). Sulfate conjugates reduced IL-6 produc-
tion by as much as 99% of control levels, suggesting sulfation
of PCA has the greatest impact on anthocyanin bioactivity
in the present model. The bioactivity of VA has previously
been reported in, in vitro models by Kim et al. [20], where VA
reduced IL-6 production in LPS-induced mouse peritoneal
macrophages. Furthermore, in the present study VA reduced
IL-6 and VCAM-1, under both stimulated conditions (oxLDL
and CD40L), suggesting significant anti-inflammatory activ-
ity. With regards to the other phase II conjugated derivatives
of PCA tested (PCA-3-glucuronide, PCA-4-glucuronide, PCA-
3-sulfate, PCA-4-sulfate, VA-4-sulfate and IVA-3-sulfate), this
is the first in vitro study to report their anti-inflammatory ac-
tivity and provides evidence that metabolites of anthocyanins
may contribute to reducing CVD risk by altering expression
of inflammatory mediators.
In CD40L-stimulatedHUVECs, C3G and 7metabolites re-
duced IL-6 protein production (between 41 and 96%ofCD40L
control) at one or more concentration tested. C3G and its
B-ring degradation product, PCA, significantly reduced IL-6
production (Fig. 4B),whilst PGAdidnot, again suggesting the
catechol group imparts some anti-inflammatory activity un-
der CD40L-stimulated conditions.However, in contrast to the
oxLDL stimulated cell model, further metabolic conjugation
of the catechol group does not appear to significantly reduce
this activity. Of the conjugated metabolites of PCA tested,
all compounds except PCA-4-glucuronide, VA-4-sulfate and
ferulic acid, reduced CD40L-induced IL-6 production, with
a maximum reduction observed for PCA-4-sulfate (95.8%
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 5. CD40L-stimulated VCAM-1 protein production in HUVECs co-incubated with C3G, phenolic metabolites or CD40L controls for
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reduction relative to CD40L control), suggesting sulfate con-
jugation has the greatest impact on anthocyanin bioactivity
under the present CD40L-stimulated conditions.
In CD40L-stimulated HUVECs, C3G and 6 metabolites
significantly reducedVCAM-1production (Fig. 5), whereC3G
and both its degradation products, PCA and PGA, reduced
CD40L-induced VCAM-1 (Fig. 5B). Of the conjugates of PCA
tested, ferulic acid had the greatest effect (Fig. 5G). The ef-
fects of sulfate and glucuronide conjugation were less ap-
parent (Fig. 5D and E), which is in contrast to the effects
observed for CD40L-induced IL-6, where sulfate conjugated
PCA resulted in the greatest reductions in IL6 production.
The findings from the present study provide support that
anthocyanin metabolites possess anti-inflammatory activity
and the conjugation of the catechol group on the phenolic
metabolites often leads to increased bioactivity. This differen-
tial bioactivity between parent and metabolite has also been
reported for conjugated forms of other flavonoids, such as
methylated (-)-epicatechin and sulfated and glucuronidated
quercetin [32–34].
To the best of our knowledge, this is the first in vitro
study to examine the effects of metabolites of C3G on IL-6
and VCAM-1 in CD40L-stimulated endothelial cells. Previ-
ous studies using differing in vitro models have reported
the anti-inflammatory activity of PCA. For example, signif-
icant reductions in VCAM-1 protein production have been
reported [15, 35] in LPS–induced RAW264.7 and TNF--
induced bovine aortic endothelial cells co-incubated with
PCA; which is in line with the present study where PCA
reduced CD40L-induced VCAM-1 by greater than 26% of
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 6. Change in CD40L-stimulated
IL-6 and VCAM-1 mRNA in HUVECs
co-incubated with C3G and phenolic
metabolites or CD40L controls for 24 h.
(A) IL-6 mRNA fold change in cells co-
incubated C3G or phenolic metabolites
(10 M) with or without D1.1 cells (1 ×
106 cells/well). (B) VCAM-1 mRNA fold
change in cells co-incubated with C3G
or phenolicmetabolites (10M)with or
without D1.1 cells (1 × 106 cells/well).
All data graphically expressed as mean
fold change (± SD, n = 3) relative to
un-stimulated (basal) IL-6 and VCAM-
1 mRNA levels. *p  0.05 (ANOVA
with Tukey post-hoc) relative to CD40L-
stimulated control. C3G, cyanidin-3-
glucoside; PCA, protocatechuic acid;
PGA, phloroglucinaldehyde; VA, vanil-
lic acid; IVA, isovanillic acid; PCA-3-
Sulf, PCA-3-sulfate; IVA-3-Sulf, IVA-3-
sulfate; FA, ferulic acid.
controls. The effects of PCA on TNF--induced VCAM-1 has
also been observed previously [15], although at much higher
concentrations (20 M) than utilized in the present study;
where we observed effects on VCAM-1 protein production at
concentrations as low as 1 M.Metabolite concentrations are
reported to reach 1–2 M in the plasma of human volunteers
[18], which is in line with the concentrations utilized in the
present investigation and below those utilized in many pre-
vious studies. Moreover, in a 13C-labelled C3G bioavailability
study in humans, Czank et al. reported 0.14 M of C3G in
2 h serum samples [18], and C3G was bioactive at this con-
centration under CD40L stimulated conditions in the present
investigation, suggesting that C3Gmay also contribute to the
anti-inflammatory effect in vascular endothelium; albeit for a
limited time post consumption.
It is worth noting that we observed differential effects un-
der different stimulus for several of the metabolites studied.
For example, IVA reduced IL-6 protein production signifi-
cantly in CD40L-stimulated HUVECs (by 56–73% of CD40L
control) but had no effect on oxLDL-challenged HUVECs
(Figs. 2C and 4C). Similarly, ferulic acid significantly re-
duced oxLDL-induced IL-6 production (by 32–42% of oxLDL
control) but did not alter CD40L-stimulated IL-6 production
(Figs. 2G and 4G). Together these data indicate that the anti-
inflammatory activity of anthocyanin metabolites differs de-
pending on the inflammatory stimulus present, suggesting
that these compounds may act by targeting unique signalling
pathways (i.e., unique to either CD40L or oxLDL signaling)
potentially through acting on tumor necrosis factor alpha
receptor associated factor-2 (TRAF-2) [14] during CD40L sig-
naling and LOX-1 (oxLDL receptor) during oxLDL signalling
[36]. As such, this ability to influence multiple pathways may
ultimately result in additive effects on CVD risk; however,
it is clear that further research is necessary to establish the
direct pathways affected.
In most cases, metabolites that reduced protein levels of
IL-6 and VCAM-1 also reduced IL-6 and VCAM-1 mRNA lev-
els. In oxLDL-stimulated HUVECs, all bioactive compounds,
except ferulic acid, reduced IL-6 mRNA levels between 55
and 83% of controls. Similarly, in CD40L-stimulated HU-
VECs, all compounds except IVA reduced mRNA levels of
IL-6 (between 85 and 95% of the CD40L control); indicat-
ing that these metabolites alter IL-6 protein production by
inhibiting CD40L-induced IL-6 mRNA induction. CD40L-
induced VCAM-1 mRNA levels were also reduced by PCA,
PGA, VA and ferulic acid, indicating bioactivity at the transla-
tional level. While this evidencemay explain the link between
gene expression and protein level, in several instances the
correlation between protein (Figs. 2 and 4 and 5) and mRNA
(Figs. 3 and 6) was not apparent. Such divergence may be the
result of post translational modification (PTM) of IL-6 and
VCAM-1, as IL-6 is subject to phosphorylation and glycosyla-
tion [37–39] and a proteolytic cleavage is required to release
membrane bound VCAM-1 to produce soluble VCAM-1 [40].
The present study was an initial step in understanding the
bioactivity of anthocyanin metabolites. The primary goal of
the present study was to investigate whether the metabolism
of anthocyanins results in increased or decreased activity
relative to the parent unmetabolised structure. A possible
mechanism by which metabolites may regulate mRNA lev-
els of IL-6 and VCAM-1 is by modulating the activation
of NF-B, as IL-6 and VCAM-1 are regulated by NF-B.
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Anthocyanin-enriched extracts have been shown to inhibit
the activation of NF-B in, in vitro studies, where blueber-
ries [17] and black rice extract [35] reduced NF-B activa-
tion. Furthermore, PCA, VA and ferulic acid, in various in
vitro models have been demonstrated to inhibit NF-B ac-
tivation [19, 20, 41]. C3G has also been reported to attenuate
NF-B through impairing the translocation of TRAF-2 to lipid
rafts in endothelial cells [14]. Lastly, the reduced size and al-
tered solubility of the metabolites could influence membrane
penetration and increase access to intracellular mechanisms
[42, 43]
The present study examined the effect of anthocyanin
metabolites at three dietary relevant concentrations (0.1, 1
and 10 M), where the dose response appeared non-linear
except in the case of VA, which appeared to reduce CD40L-
inducedVCAM-1production in a linear dose-dependentman-
ner (Fig. 5C). This observed non-linear dose response for
the other treatments has previously been reported for other
flavonoids such as quercetin and genistein and may have
important biological implications [44, 45].
While the present study provides novel insights into the
anti-inflammatory activity of recently identified anthocyanin
metabolites, there are several limitationswith this experimen-
tal approach. First, the measurement of IL-6 and VCAM-1
protein under stimulated conditions was carried out at a sin-
gle time point (at 24 h stimulation) and the effects may differ
following shorter periods of incubation [46,47]. Further time-
course studies are required to establish time-dependent ef-
fects. The present study also used a co-incubationmodel of ac-
tivity and effects may differ following pre- or post-stimulation
(CD40L or oxLDL) with anthocyanin metabolites. Addition-
ally, the investigation of the effect of bioactive metabolites
on mRNA levels of IL-6 and VCAM-1 was performed only at
the maximal treatment concentration utilised in the screen
(i.e., 10 M). The highest dose in the screen was chosen to
demonstrate maximal activity at the translational level, how-
ever responses may have differed at 0.1 or 1 M. Future work
should explore a greater range of physiologically appropriate
concentrations. This initial screen of anthocyanin metabolite
activity was designed to establish if the metabolism of an-
thocyanins altered their anti-inflammatory activity; and here
we explored activity on only a limited number of chemokines
(IL-6 and VCAM1), however an extensive array of biologically
important chemokines, such asMCP-1, ICAM-1, IL-12, IL-10,
IL-1 (to name a few) require future study.
The present study used D1.1 cells as a primary source of
CD40L. D1.1 (Jurkat) cells are T-cells that express high lev-
els of CD40L and are much more cost effective than using
recombinant CD40L for large screening experiments. This
could also be considered a limitation of the present work as
the D1.1 cells add a level of ambiguity to the model system.
However, as our primary aimwas to determine ifmetabolism
of anthocyanins alters their bioactivity, D1.1 cells provided a
cost effective alternative to recombinant CD40L. In addition,
the use of D1.1 cells as a primary source of CD40L to investi-
gate inflammatory responses is a common method reported
in the literature [48–50]. However, the results should be con-
firmed in future studies using pure recombinant CD40L (sol-
uble CD40L). In addition, even though HUVECs are a well-
established model for endothelial cell research, these results
should be confirmed using in vivo studies. Finally, soluble
VCAM-1 was quantified in the current investigation as op-
posed to membrane bound VCAM. The use of membrane
bound over soluble VCAM-1 as a marker of CVD risk has
been a current topic of discussion in the literature and Videm
et al. has recently published a study summarizing the rela-
tionship between VCAM-1 mRNA levels and concentration
of membrane bound and soluble VCAM-1 [40]. The authors
concluded that there was no trend between mRNA levels and
VCAM-1protein thatwould favour the selection ofmembrane
bound VCAM-1 over soluble VCAM-1 as a biomarker of ac-
tivity. The study concluded that soluble VCAM-1 appeared
to be a better biomarker than membrane bound VCAM-1 in
HUVECs. Future work could however verify these associa-
tions with membrane bound VCAM-1 protein to establish if
anthocyanin metabolites interfere with its proteolytic cleav-
age at themembrane, as previously suggested [40]. This aside,
the present study provides a screen for the biological activity
of a wide range of previously unstudied anthocyanin metabo-
lites and provides a clear future direction for anthocyanin
research.
Our novel data highlight that C3G metabolites are bioac-
tive at physiologically relevant concentrations. Further re-
search is required to establish not only the underlying mech-
anisms involved but also the physiological relevance of these
findings to humans. These studies provide the first evidence
that anthocyanin metabolites possess anti-inflammatory ef-
fects that are likely to contribute to the reduced risk of CVD
associated with increased habitual intake of anthocyanins [1].
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